These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 29167939)

  • 1. The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?
    Harrison RA
    Semin Immunopathol; 2018 Jan; 40(1):15-35. PubMed ID: 29167939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the alternative complement pathway.
    Fearon DT
    CRC Crit Rev Immunol; 1979 Nov; 1(1):1-32. PubMed ID: 162484
    [No Abstract]   [Full Text] [Related]  

  • 3. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.
    Corvillo F; Bravo García-Morato M; Nozal P; Garrido S; Tortajada A; Rodríguez de Córdoba S; López-Trascasa M
    Clin Exp Immunol; 2016 Apr; 184(1):118-25. PubMed ID: 26660535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.
    Marinozzi MC; Chauvet S; Le Quintrec M; Mignotet M; Petitprez F; Legendre C; Cailliez M; Deschenes G; Fischbach M; Karras A; Nobili F; Pietrement C; Dragon-Durey MA; Fakhouri F; Roumenina LT; Fremeaux-Bacchi V
    Kidney Int; 2017 Nov; 92(5):1232-1241. PubMed ID: 28712854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins.
    Schreiber RD; Pangburn MK; Lesavre PH; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1978 Aug; 75(8):3948-52. PubMed ID: 279011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.
    Farries TC; Lachmann PJ; Harrison RA
    Biochem J; 1988 May; 252(1):47-54. PubMed ID: 3421908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The alternative pathway of complement.
    Pangburn MK; Müller-Eberhard HJ
    Springer Semin Immunopathol; 1984; 7(2-3):163-92. PubMed ID: 6238433
    [No Abstract]   [Full Text] [Related]  

  • 8. [The alternative complement pathway].
    Jouvin MH; Kazatchkine M
    Pathol Biol (Paris); 1983 Dec; 31(10):839-46. PubMed ID: 6230588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of properdin in the assembly of the alternative pathway C3 convertases of complement.
    Hourcade DE
    J Biol Chem; 2006 Jan; 281(4):2128-32. PubMed ID: 16301317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus.
    Kostavasili I; Sahu A; Friedman HM; Eisenberg RJ; Cohen GH; Lambris JD
    J Immunol; 1997 Feb; 158(4):1763-71. PubMed ID: 9029114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.
    Medicus RG; Götze O; Müller-Eberhard HJ
    J Exp Med; 1976 Oct; 144(4):1076-93. PubMed ID: 978134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin.
    Alcorlo M; Tortajada A; Rodríguez de Córdoba S; Llorca O
    Proc Natl Acad Sci U S A; 2013 Aug; 110(33):13504-9. PubMed ID: 23901101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stabilization of homologous and heterologous cell-bound amplification convertases, C3bBb, by C3 nephritic factor.
    Daha MR; Van Es LA
    Immunology; 1981 May; 43(1):33-8. PubMed ID: 6166544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular biology and chemistry of the alternative pathway of complement.
    Müller-Eberhard HJ; Schreiber RD
    Adv Immunol; 1980; 29():1-53. PubMed ID: 6158260
    [No Abstract]   [Full Text] [Related]  

  • 15. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation.
    Paixão-Cavalcante D; López-Trascasa M; Skattum L; Giclas PC; Goodship TH; de Córdoba SR; Truedsson L; Morgan BP; Harris CL
    Kidney Int; 2012 Nov; 82(10):1084-92. PubMed ID: 22854646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
    Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
    Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase.
    Bettoni S; Bresin E; Remuzzi G; Noris M; Donadelli R
    J Biol Chem; 2016 Apr; 291(15):8214-30. PubMed ID: 26903516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel mechanism of complement inhibition unmasked by a tick salivary protein that binds to properdin.
    Tyson KR; Elkins C; de Silva AM
    J Immunol; 2008 Mar; 180(6):3964-8. PubMed ID: 18322205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of C3b(2)--IgG complexes with complement proteins properdin, factor B and factor H: implications for amplification.
    Jelezarova E; Vogt A; Lutz HU
    Biochem J; 2000 Jul; 349(Pt 1):217-23. PubMed ID: 10861231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Properdin and complement activation: a fresh perspective.
    Hourcade DE
    Curr Drug Targets; 2008 Feb; 9(2):158-64. PubMed ID: 18288967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.